SACUBITRIL-VALSARTAN

Course overview

SACUBITRIL/VALSARTAN IS THE FIRST AGENT TO BE APPROVED IN A NEW CLASS OF DRUGS CALLED ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI). THE MEDICATION IS FDA-APPROVED TO TREAT PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) WITH NYHA CLASS II, III, OR IV. SACUBITRIL/VALSARTAN IS TO BE USED IN PLACE OF AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR OR ANGIOTENSIN II RECEPTOR BLOCKER AND CONJUNCTION WITH OTHER STANDARD HEART-FAILURE TREATMENTS (BETA-BLOCKER, ALDOSTERONE ANTAGONIST). PATIENTS MUST BE ABLE TO TOLERATE ACEI OR ARB BEFORE STARTING ON SACUBITRIL/VALSARTAN. THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM OF ACTION, METHODS OF ADMINISTRATION, IMPORTANT ADVERSE EFFECTS, CONTRAINDICATIONS, TOXICITY, AND MONITORING OF SACUBITRIL/VALSARTAN, SO PROVIDERS CAN DIRECT PATIENT THERAPY IN CONDITIONS WHERE IT IS INDICATED IN THE TREATMENT OF PATIENTS WITH HEART FAILURE AND RELATED CONDITIONS.